Chugai Pharmaceutical Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody.
The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE.
LTD. to develop novel therapies for age-related diseases.
The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943.
Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
| Country | Japan |
| Founded | 1925 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 5,026 |
| CEO | Osamu Okuda |
Contact Details
Address: Nihonbashi Mitsui Tower Chuo, 103-8324 Japan | |
| Phone | 81 3 3281 6611 |
| Website | chugai-pharm.co.jp |
Stock Details
| Ticker Symbol | CHGCF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3519400000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Osamu Okuda | President, Chief Executive Officer and Chairman |
| Iwaaki Taniguchi | Executive Vice President, Head of Finance Supervisory Division, Chief Financial Officer and Director |
| Toshiya Sasai | Executive of Investor Relations Group and Corporate Communications Department |
| Junichi Takano | Head of Marketing and Sales Division |
| Shinji Hidaka | Executive Vice President |
| Tetsuya Yamaguchi | Executive Vice President |
| Yoshiyuki Yano | Executive Vice President |
| Kosuke Iijima | Head of PHC Solution Department |
| Dr. Tomoyuki Igawa Ph.D. | Vice President and Head of Research Division |
| Dr. Kaori Ouchi | Executive Vice President |